session 8 - bio17-dr. thani jambulingam · 2017. 6. 14. · #bio2017 r&d marketing interface...
TRANSCRIPT
![Page 1: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/1.jpg)
![Page 2: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/2.jpg)
#BIO2017
R&DMarketingInterface
Dr.ThaniJambulingamPh.D.,Professor,PfizerFellow,ArrupeResearchFellow
DepartmentofPharmaceuticalandHealthcareMarketingErivanK.HaubSchoolofBusiness
SaintJoseph’sUniversityPhiladelphia,PA19131
13thAnnualBiotechnologyEntrepreneurshipBootCampBIOInternationalConvention
June18,2017
![Page 3: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/3.jpg)
#BIO2017
LearningObjectives• Highlighttheimportanceofcommercialteaminputintoproduct
developmentstrategyinaearlystagebiotech/medicaldevicecompany
• Understandtheroleofmarketinginearlystagecompaniestoshapetheproductlifecycletoachievethebestcommercialsuccess.
• Describetheprocessofcreatingacommerciallyappealingtargetproductprofile(TPP).
• LearnhowtodevelopaTPPframeworktodeliverbetteroutcomes.
![Page 4: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/4.jpg)
#BIO2017Trends• Healthcarepriority:costcontrol,accessandpricetransparency
• Decreasingaccesstophysicians
• Shiftingpowerbalancetowardpayers
• Reimbursementmodelsfocusonvalue/outcome
• Growthofalternativedeliverymodelsandpartnerships
• Digitaltransformationenhancingpatientcentricityandengagement
![Page 5: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/5.jpg)
#BIO2017
PharmaLossofExclusivity
Source:MedicinesuseandspendingintheU.S.– IMSReport, May2017
![Page 6: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/6.jpg)
#BIO2017
SegmentsofPharmaceuticalMarket
Source:UnderstandingtheNewCommercialModelsinthePharmaceuticalIndustry– AnIMSReport,2009
![Page 7: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/7.jpg)
#BIO2017
GrowthofSpecialtyProducts
Source:MedicinesuseandspendingintheU.S.– IMSReport, May2017
![Page 8: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/8.jpg)
#BIO2017
Brandsvs.GenericsShares
Source:MedicinesuseandspendingintheU.S.– IMSReport, May2017
![Page 9: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/9.jpg)
#BIO2017
Brandsvs.GenericsShares
Source:MedicinesuseandspendingintheU.S.– IMSReport, May2017
![Page 10: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/10.jpg)
#BIO2017CMSFrameworkCategorizingPaymentstoProviders
Description
MedicareFee-for-Serviceexamples
§ Paymentsarebasedonvolumeofservicesandnotlinkedtoqualityorefficiency
Category1:FeeforService–NoLinktoValue
Category2:FeeforService–LinktoQuality
Category3:AlternativePaymentModelsBuiltonFee-for-ServiceArchitecture
Category4:Population-BasedPayment
§ Atleastaportionofpaymentsvarybasedonthequalityorefficiencyofhealthcaredelivery
§ Somepaymentislinkedtotheeffectivemanagementofthepopulationoranepisodeofcare
§ Paymentsstilltriggeredbydeliveryofservices,butopportunitiesforsharedsavingsor2-sidedrisk
§ Paymentisnotdirectlytriggeredbyservicedeliverysovolumeisnotlinkedtopayment
§ Cliniciansandorganizationsarepaidandresponsibleforthecareofabeneficiaryforalongperiod(e.g.,≥1year)
§ LimitedinMedicarefee-for-service
§ MajorityofMedicarepaymentsnowarelinkedtoquality
§ Hospitalvalue-basedpurchasing
§ PhysicianValueModifier
§ Readmissions/HospitalAcquiredConditionReductionProgram
§ AccountableCareOrganizations§ Medicalhomes§ Bundledpayments§ ComprehensivePrimaryCareinitiative
§ ComprehensiveESRD§ Medicare-MedicaidFinancialAlignmentInitiativeFee-For-ServiceModel
§ EligiblePioneerAccountableCareOrganizationsinyears3-5
§ Marylandhospitals
Source:RajkumarR,ConwayPH,TavennerM.CMS─engagingmultiplepayersinpaymentreform.JAMA2014;311:1967-8.
![Page 11: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/11.jpg)
#BIO2017
2016
30%
85%
2018
50%
90%
CMSTargetPercentageof‘AlternativePaymentModels’by2016- 2018
2014
~20%
>80%
20110%
~70%
GoalsHistoricalPerformance
AllMedicareFFS(Categories1-4)FFSlinkedtoquality(Categories2-4)Alternativepaymentmodels(Categories3-4)
Source:RajkumarR,ConwayPH,TavennerM.CMS─engagingmultiplepayersinpaymentreform.JAMA2014;311:1967-8.,CMSwebsite
![Page 12: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/12.jpg)
#BIO2017WhatProportionoftheLaunchesareInnovative?
InthevaluedrivenpostAccountableCareAct(ACA)eraonly24percentofthelaunches
wouldbetrulyinnovative
Source:BeyondtheStorm:TheLaunchExcellenceintheNewNormal,McKinseyReport2013,pp.6
![Page 13: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/13.jpg)
#BIO2017
InnovativeProduct
Adifferentiatedproduct(solution)thatoffersameaningful advantage(value)overexisting
treatmentsforagivencondition
Howcanmarketingshapetheproduct?
![Page 14: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/14.jpg)
#BIO2017
4 Ps, As, & Objectives of Marketing
4Ps 4As Objectives
Product Acceptability AddressUnmet Needs
Price Affordability ValuetoPayers
Place Accessibility CreateConvenience
Promotion Awareness CommunicationofValue
![Page 15: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/15.jpg)
#BIO2017HowtoImprovetheProbabilityofSuccess?
$Development Launch Patent Loss
TimeLaunch
++
- -
Research
•SignificantsunkcostsduringR&Dandpoormarketperformanceoftheproductwillbecostly•Canearlystageandcontinuousmarketinginputchangethis?
![Page 16: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/16.jpg)
#BIO2017
IdealProductLifeCycle
Simultaneous and smooth global launch
R&D Efficiencies /Effectiveness
$Development Launch Patent Loss
TimeLaunch
++
- -
Research
![Page 17: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/17.jpg)
#BIO2017
Meeting StakeholdersNeeds
Simultaneous and smooth global launch
R&D Efficiencies /Effectiveness
$Development Launch Patent Loss
TimeLaunch
++
- -
Research
![Page 18: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/18.jpg)
#BIO2017EarlyMarketingInputCanImproveProductSuccess
Simultaneous and smooth global launch
R&D Efficiencies /Effectiveness
$ Development Launch Patent Loss Time
Launch
++
- -
Research
MarketingInput
![Page 19: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/19.jpg)
#BIO2017WhatwillcollaborationachieveFrom…..
Org
aniz
atio
nal
Rol
esSt
ages
of
Dev
elop
men
t
Discovery
Pre-Clinical
Manufacturing
Marketing
Sales
RegulatoryClinical
Discovery ExploratoryDevelopment
FullDevelopment Registration Launch Post-Launch
Growth
IP HEOR/Pricing/Reimbursement
![Page 20: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/20.jpg)
#BIO2017WhatwillcollaborationachieveTo…..anIntegratedCommercialModel
Org
aniz
atio
nal
Rol
esSt
ages
of
Dev
elop
men
t
Discovery Marketing
Discovery ExploratoryDevelopment
FullDevelopment Registration Launch Post-Launch
Growth
Development(preclinical, clinical, regulatory)
IntellectualProperty
UpstreamRoleofMarketingisCriticalfordevelopinganIdealLabelandProductSuccess!
HEOR/ PricingReimbursement Manufacturing
Sales
![Page 21: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/21.jpg)
#BIO2017
What is TPP?
21
• In2007FDAcreatedaguidancedocumentonTPPasastrategicprocessdevelopmenttooltofacilitateeffectivecommunicationbetweentheindustryandreviewstaff
• TPPisthedirectionaltoolthathasasignificantimpactonthedrugdevelopmentprocessandinparticular,itsmarketingorganization
• TPPconvertdiscoveriesintocompanies!
• MarketingaspartofcommercialteamcanshapetheTPP
![Page 22: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/22.jpg)
#BIO2017Startwithendinmind:Howshouldthelabellooktomeetcustomerneeds?
SustainableTPPsatisfyingmarketneeds
Patient
HCP
Pharmacist
Payer
Conductmarketresearchtogaininsightsoncustomerneeds
![Page 23: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/23.jpg)
#BIO2017HowcanTPPbeshapedbyMarketing?
• Indication
• Dosageform
• Dose,frequency
• Differentiation
– Efficacy
– Safety
– Economic
AttributesShapedbyMarketing
n Proposedindication
n Developformulation
n Developtrade-dress
n Establishefficacy/superiority
n Establishsafetyadvantage
n Developforpediatricuse
n Pharmacoeconomicdata
TPP
![Page 24: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/24.jpg)
#BIO2017
Whoshouldworktogether?
SustainableTPPsatisfyingmarketneeds
Regulatory
Marketing
Clinical
Research
Goal:Todeliverstrongdevelopmentplanwith
superiorclinicalperformance,patientbenefitandhealtheconomicvalue
![Page 25: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/25.jpg)
#BIO2017
TargetMarketProfile(TMP)
StrategicTargetProfile(STP)TargetProductProfile(TPP) DynamicSummaryof
thedrugthatismostlikelytolaunch
Avisionofhowtheproductshouldmeet
theneedsofthemarket
Delineatestheunmetneedsofthemarketforwhichtheproductis
viable
STRATEGIC FRAMEWORK
Source:Tebbey,PaulW.andCharlesRink,“TPP:ARenaissanceforitsDefinitionandUse,JournalofMedicalMarketing,Vol.9(4),301-307.
![Page 26: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/26.jpg)
#BIO2017StrategicFrameworkTarget MarketProfile(TMP)
Purpose Captures allthekeyinformationaboutthemarket
Content Therapeuticareas/diseases• UnmetNeed• PatientPopulations• Driversofuse• Competitiveassessment• Economiccostofdisease
Rigidity CreatebeforetheSTPorTPPDetailsareupdatedasfindingsemerge,butcorefactschangeonlyinresponsetomajormarketevents
![Page 27: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/27.jpg)
#BIO2017StrategicFrameworkTarget MarketProfile(TMP) StrategicTargetProfile(STP) TargetProductProfile(TPP)
Purpose Captures allthekeyinformationaboutthemarket
Avisionforaproductthatwillmeettheneedsofthemarket
Content Therapeuticareas/diseases• UnmetNeed• PatientPopulations• Driversofuse• Competitiveassessment• Economiccostofdisease
Target attributes(desiredprofile)• Valuedrivers/Positioning• GlobalReach• Pricing/Reimbursement• PatientShare• Revenue– Profitability• Pharmacoeconomics• Investments(R&D,COGS,SGA)• Costofgoods• Licenses,Royalties
Rigidity CreatebeforetheSTPorTPPDetailsareupdatedasfindingsemerge,butcorefactschangeonlyinresponsetomajormarketevents
Set atthebeginningofclinicaldevelopmentandupdatedonlywhennecessitatedbychangesintheTMP
üPositioningüGlobalSalesForecastüDevelopmentalLogic
üRegulatoryandReimbursement
StrategyüProductValue
![Page 28: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/28.jpg)
#BIO2017StrategicFrameworkTarget MarketProfile(TMP) StrategicTargetProfile(STP) TargetProductProfile(TPP)
Purpose Captures allthekeyinformationaboutthemarket
Avisionforaproductthatwillmeettheneedsofthemarket
Arecordofthedrugthatismostlikelytolaunch
Content Therapeuticareas/diseases• UnmetNeed• PatientPopulations• Driversofuse• Competitiveassessment• Economiccostofdisease
Target attributes(desiredprofile)• Valuedrivers• Global• Pricing/Reimbursement• PatientShare• Revenue– Profitability• Pharmacoeconomics• Investments(R&D,COGS,SGA)• Costofgoods• Licenses,Royalties
Indications andusage(label)• Dosingandadministration• Contraindications• Warningsandprecautions• Adversereactions• Description• ClinicalPharmacology• ClinicalStudies• Storageandhandling
Rigidity CreatebeforetheSTPorTPPDetailsareupdatedasfindingsemerge,butcorefactschangeonlyinresponsetomajormarketevents
Set atthebeginningofclinicaldevelopmentandupdatedonlywhennecessitatedbychangesintheTMP
Updatedasclinicalandpharmacologic findingsemergeandinresponsetoguidancefromregulatoryauthorities
![Page 29: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/29.jpg)
#BIO2017QuestionsthatneedstobeaskedandansweredduringtheTPPprocess
Source:BeginwithEndinMind– WhitePaperPremierResearch,2015
![Page 30: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/30.jpg)
#BIO2017
PortfolioOptimization– Go/NoGo
• Specification– TPP– Current,Minimal,Ideal&Expected
• Resources– ManpowerandCost
• Timeline– MilestoneSchedule
• Risk– ProbabilityofSuccess(Technical,Commercial)
![Page 31: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/31.jpg)
#BIO2017TPPinGo/NoGoDecisions
![Page 32: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/32.jpg)
#BIO2017TPPCriteria
![Page 33: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/33.jpg)
#BIO2017
SampleTPP
Source:https://neuroscienceblueprint.nih.gov/resources/target-product-profile.htm,accessedJune14,2017
![Page 34: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/34.jpg)
#BIO2017BestDevelopmentStrategies…• Usethestrategicframework(TMP,STP)toshapeTPPanddefineclinicaland
commercialvalue
• TPPprovidesdevelopmentallogicandsavescosttodrugdiscoveryanddevelopmentprogramandmeettheneedsofthemarketplace
• EncouragesrightdialogwithinthecompanyandwiththeFDAtooptimizelabelandpromotabilityforcommercialsuccess
• Theidealdevelopmentstrategyidentifykeymilestones-criticaltimes,whentheabilityofaprojecttoattainitsTPPcanbeassessed- andestablish“go/nogo”successcriteria
![Page 35: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/35.jpg)
#BIO2017
MarketingCreate“BeyondthePill”Solution
CoreProduct
IndicationsDosageForm
DoseFrequencyEfficacySafety
![Page 36: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/36.jpg)
#BIO2017MarketingCreate“BeyondthePill”Solution
CoreProduct
IndicationsDosageForm
DoseFrequencyEfficacySafety
MarketingInsights
Marketingshouldshapethe“Label”fortheproduct
![Page 37: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/37.jpg)
#BIO2017MarketingCreate“BeyondthePill”Solution
CoreProduct
Data
EndPointsPatientPopulation
StudyDesignPharmacoeconomics
CompetitiveComparatorsManufacturing
MarketingInsights
![Page 38: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/38.jpg)
#BIO2017MarketingCreate“BeyondthePill”Solution
CoreProduct
Data
REMSDiagnostics
DeliverySystemMonitoringSystemProductTracking
DistributionSupportSalesSupport
LoyaltyProgramsBehaviorModification
Programs
MarketingInsights
Services
![Page 39: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/39.jpg)
#BIO2017MarketingCreate“BeyondthePill”Solution
CoreProduct
Data
CodingReimbursementFormularyStatusRiskSharing
PayforPerformanceCoupons
PatientAssistance
MarketingInsights
Services
Financial
![Page 40: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/40.jpg)
#BIO2017MarketingCreate“BeyondthePill”Solution
CoreProduct
Data
Services
Financial
PerceivedValue
MarketingInsightstoManageTrustandPerceivedValue
![Page 41: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/41.jpg)
#BIO2017
Source:Tyndallet.al.TheTPPasatoolforregulatorycommunication:advantageousbutunderused,Nature,March2017,pp.156
ResearchshowsTPPisvaluablebutunderused
![Page 42: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/42.jpg)
#BIO2017
Source:Tyndallet.al.TheTPPasatoolforregulatorycommunication:advantageousbutunderused,Nature,March2017,pp.156
ResearchshowsTPPValuablebutUnderused
![Page 43: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/43.jpg)
#BIO2017FinalRemarks• Startwithendinmind• StrengthentheR&DMarketing(Commercial)interface• Assemblecrossfunctionalcommercialdevelopmentteam• Assignamarketingmanagertothedevelopmentteam• Incorporatemarketresearchandcompetitiveintelligencein
clinicaltrialplanningandlabeldevelopment• Engagepayersearlyontogetvaluableinputindevelopment• SuccessiswhenthefinalversionofTPPissimilartotheannotated
draftlabeling!
![Page 44: Session 8 - BIO17-Dr. Thani Jambulingam · 2017. 6. 14. · #BIO2017 R&D Marketing Interface Dr. Thani Jambulingam Ph.D., Professor, Pfizer Fellow, Arrupe Research Fellow Department](https://reader033.vdocuments.mx/reader033/viewer/2022060723/6083ab23f5ab7c0de84c0378/html5/thumbnails/44.jpg)
#BIO2017
Questions?